Clinical Trial Recruitment Lab

The Clinical Trial Recruitment Lab (CTRL) is an interdisciplinary hub for piloting and evaluating innovative ideas with the potential to increase access to clinical trials and expand diversity in clinical trial populations. CTRL’s goal is to coordinate the resources and expertise necessary to conduct pilot projects that test novel trial recruitment strategies, disseminate findings and share best practices to speed the pace of drug development. CTRL brings together stakeholders from academia, industry and philanthropy to create a platform through which innovative ideas can be piloted and tested in the real world.

Program Leadership

Paul Aisen, MD

Director, Alzheimer’s Therapeutic Research Institute
Professor of Neurology, Keck School of Medicine of USC

Phyllis Barkman Ferrell, DrPH, MBA

Nonresident Scholar, USC Schaeffer Institute

Dana Goldman, PhD

Founding Director, USC Schaeffer Institute for Public Policy & Government Service
University Professor of Public Policy, Pharmacy, and Economics
Special Advisor, USC Provost

Mireille Jacobson, PhD

Co-Director, Aging and Cognition Program, USC Schaeffer Center
Senior Scholar, USC Schaeffer Institute
Professor, USC Leonard Davis School of Gerontology

Desi Peneva, MS

Research Program Lead, USC Schaeffer Center

Rema Raman, PhD

Director, ATRIL
Professor of Neurology, USC Keck School of Medicine
Director, Section of Biostatistics & Section of Participant Recruitment & Retention,
Alzheimer’s Therapeutic Research Institute

CTRL News and Research View All

Remote Blood Collection Shows Promise for Alzheimer’s Research

A new study shows promise for using remote blood collection to find participants for Alzheimer's trials.

Aging

Can a Free Virtual Outreach Series Increase Alzheimer’s Disease Awareness?

USC Receives Award to Improve Diversity and Efficiency of Alzheimer’s Clinical Trials

Ongoing Studies

The Alzheimer’s Trial Recruitment Innovation Lab (ATRIL) seeks to diversify participant recruitment and accelerate the process of enrolling a representative population in preclinical and prodromal Alzheimer’s clinical trials through evidence-based science, community engagement and training.

Alzheimer’s Trial Recruitment Innovation Lab

More Clinical Trial Research View All

Evidence Base

Reforming Health Policy to Expand Cognitive Screening

It's becoming clear that early and aggressive intervention is our best hope for alleviating the tremendous suffering Alzheimer's causes. Policies must adapt to reflect this knowledge.

Featured Experts: Joseph Grogan

Perspective

Congress Must Roll Back a Key Anti-Innovation Biden-Harris Policy

Comment Letter

Comments to Representatives DeGette and Bucshon on Building on the Successes of 21st Century Cures

Perspective

Access to New Alzheimer’s Treatments Bogged Down by Medicare Policy

In The News View All

Inside Health Policy